ArticleScientific reports2025
Serum growth differentiation factor 15 associates with extra-glandular manifestations and disease activity of primary Sjögren's syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Serum growth differentiation factor 15 as a candidate biomarker associated with interstitial lung disease in primary Sjögren's syndrome: a clinical cross-sectional study.Clinical rheumatology · 2026Article
- Data-driven classification of primary Sjögren's syndrome: From cluster analysis to clinical immune phenotypes and predictive biomarkers.Journal of translational autoimmunity · 2026Article
- Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.Journal of gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent interest in growth differentiation factor 15 (GDF15) has been further heightened by its association with rheumatic diseases. GDF15 has been extensively studied as a potential diagnostic and prognostic biomarker. However, no direct evidence currently links GDF15 to primary Sjögren's syndrome (pSS). In this study, we measured serum GDF15 levels in 151 pSS patients and 61 healthy controls (HCs). GDF15 levels were significantly elevated in pSS patients compared to HCs. Receiver operating characteristic (ROC) curve analysis demonstrated that GDF15 effectively distinguished pSS patients from HCs. Notably, GDF15 levels were higher in pSS patients with extra-glandular manifestations and positively correlated with the number of such manifestations. Specifically, elevated GDF15 levels were observed in patients with pulmonary, hematological, renal, or nervous system involvement. Furthermore, GDF15 levels were significantly increased in patients with active disease compared to those in non-active stage, and ROC analysis confirmed its discriminative capacity for disease activity. Using advanced machine learning techniques, we developed an adaptive boosting model that combined GDF15 with albumin, red blood cell count, and C-reactive protein, which showed reliable predictive value for disease activity. These findings suggest that serum GDF15 may serve as a valuable biomarker for assessing disease severity and guiding treatment in pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.